Journal of Biomedical and Pharmaceutical Research
Available Online at www.jbpr.in
CODEN: - JBPRAU (Source: - American Chemical Society)
NLM (National Library of Medicine): ID: (101671502)
Index Copernicus Value 2023: 85.868
Volume 14, Issue 4; 2025, 18-41

ISSN (Online): 2279-0594
ISSN (Print): 2589-8752

Review Article

Pharmacological Management of Aggression in Dementia: Investigating the Role and Risks of Antipsychotics

Md. Javed Anjum[1], Manish Kumar[2], Aditya Kumar[3]

[1]Student, Bachelor of Pharmacy, Krishna Institute of Nursing & Paramedical Science, Samastipur, Bihar, India (Affiliated to Aryabhatta Knowledge University, Patna)
[2,3]Lecturer, Krishna Institute of Nursing & Paramedical Science, Samastipur, Bihar, India

Article Info: Received: 05-05-2025 / Revised: 27-05-2025 / Accepted: 30-06-2025
Corresponding Author: Md. Javed Anjum
DOI: https://doi.org/10.32553/jbpr.v14i4.1327
Conflict of interest statement: No conflict of interest

Abstract:

Dementia is a progressive neurodegenerative disorder characterized not only by cognitive decline but also by a range of behavioural and psychological symptoms, among which aggression poses a significant clinical challenge. Aggression in dementia is associated with increased caregiver stress, patient morbidity, early institutionalization, and elevated healthcare costs. While non-pharmacological interventions are considered the first-line approach for managing behavioural disturbances, pharmacological treatments, particularly antipsychotics, are often employed when symptoms become severe or pose a risk to the patient or others.

This literature review aims to explore the current pharmacological strategies for managing aggression in dementia, with a central focus on the use of antipsychotic medications. It delves into the neurobiological underpinnings of aggression, including alterations in neurotransmitter systems such as dopamine, serotonin, and acetylcholine, as well as structural and functional changes in specific brain regions. Both typical and atypical antipsychotics are examined in terms of their mechanisms of action, clinical efficacy, and safety profiles. Among these, risperidone and olanzapine have demonstrated modest benefits in reducing aggression, although their use is frequently accompanied by adverse effects such as extrapyramidal symptoms, sedation, metabolic disturbances, and increased risk of cerebrovascular events and mortality, particularly in elderly patients.

Regulatory agencies, including the FDA and EMA, have issued warnings concerning the use of antipsychotics in dementia, urging clinicians to weigh the risks and benefits carefully. The review further evaluates current clinical guidelines, discusses alternative pharmacologic options including antidepressants and mood stabilizers, and briefly outlines non-pharmacological strategies as adjuncts or alternatives. Additionally, the paper highlights emerging therapeutic directions, including novel drug targets and personalized medicine approaches.

Given the delicate balance between symptom control and patient safety, a cautious, individualized, and ethically sound prescribing approach is imperative. Future research should focus on safer, more effective treatments and strategies that integrate pharmacologic and holistic care for individuals with dementia experiencing aggression.

Keywords: Dementia, Cognitive impairment, Psychiatric symptom, Hospital care, Inpatient, Older people, Systematic review, Alzheimer's disease (AD)

Chapter 1: Introduction

Dementia is a chronic and progressive condition characterized by the deterioration of cognitive function beyond what might be expected from normal aging. It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. Globally, over 55 million people live with dementia, and this number is expected to rise to 78 million by 2030 and 139 million by 2050 according to the World Health Organization. Among its many manifestations, Behavioral and Psychological Symptoms of Dementia (BPSD)—including aggression, agitation, hallucinations, and delusions—are some of the most distressing for both patients and caregivers.

Aggression in dementia is not merely a behavioral issue but often a reflection of underlying neuropathological changes. This aggression can manifest as verbal outbursts, physical violence, resistance to care, or socially inappropriate behavior. It poses significant challenges for caregivers and healthcare professionals, often leading to institutionalization and poor quality of life. Hence, effective management is crucial.

Antipsychotic medications are frequently used to manage aggression in dementia, particularly when non-pharmacological interventions fail. These include both first-generation (typical) and second-generation (atypical) antipsychotics. While these agents can reduce agitation and aggression, their use is controversial due to associated risks, especially in the elderly population. Numerous studies and regulatory agencies have raised concerns about increased mortality, cerebrovascular events, and worsening cognitive decline in patients receiving antipsychotics for dementia-related symptoms.

Despite these concerns, antipsychotics remain widely prescribed. The decision to use these drugs involves a delicate balance between mitigating behavioral disturbances and avoiding harm. Clinical guidelines generally recommend non-pharmacological interventions as first-line therapy, reserving antipsychotics for severe cases with significant risk of harm.

This literature review aims to critically examine the role of antipsychotics in managing dementia-associated aggression. It will explore their mechanisms of action, clinical efficacy, and safety profile. Additionally, it will review current clinical guidelines, ethical issues in prescribing, and future directions, including emerging pharmacological strategies and alternatives. Given the aging global population and the growing burden of dementia, this review is both timely and relevant. It is essential to understand not only the pharmacological tools available but also their limitations and potential for harm. An evidence-based and patient-centered approach is needed to improve care outcomes while minimizing adverse effects.

In this review, special emphasis will be placed on:

- The neurobiology of aggression in dementia.
- Classes and mechanisms of antipsychotics used.
- Comparative data on efficacy and safety.
- Review of regulatory guidance such as the FDA black box warning.
- Ethical, legal, and caregiver perspectives.
- Alternatives such as SSRIs, anticonvulsants, and non-drug interventions.
- Promising new research in neuropsychiatric management.

Through this comprehensive review, the project will contribute to better clinical decision-making and improved patient care for one of the most vulnerable populations in healthcare: elderly individuals with dementia.

Chapter 2: Pathophysiology of Aggression in Dementia

Introduction

Aggression is a hallmark neuropsychiatric symptom of dementia, falling under the broad spectrum of Behavioural and Psychological Symptoms of Dementia (BPSD). These symptoms, which include agitation, delusions,

hallucinations, depression, apathy, and disinhibition, severely compromise quality of life and caregiving environments. Aggression is particularly challenging as it increases caregiver burden, risk of institutionalization, and patient morbidity. Understanding the underlying neurobiological, neurochemical, and anatomical factors responsible for aggression in dementia is essential for developing targeted and effective interventions.

Overview of Dementia and Aggression

Dementia is a clinical syndrome caused by various neurodegenerative and vascular disorders, with Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD), and vascular dementia (VaD) being the most common. Aggression is especially prevalent in AD and FTD. The clinical expression of aggression may vary depending on the type of dementia, severity of disease, environmental stressors, and underlying neuropathology.

Neuroanatomical Basis of Aggression

Aggression is regulated by a complex network of brain structures including the prefrontal cortex (PFC), amygdala, hippocampus, anterior cingulate cortex (ACC), and hypothalamus. Disruption in this neural circuitry due to neurodegenerative pathology can lead to poor impulse control, emotional dysregulation, and increased aggression.



Figure 1: Neural circuits involved in aggression

Prefrontal Cortex

The PFC, especially the orbitofrontal and dorsolateral regions, plays a critical role in executive functions, emotional regulation, and behavioural inhibition. Degeneration or hypofunction in this area, commonly seen in FTD and advanced AD, results in impulsivity and disinhibited aggressive outbursts.

Amygdala and Limbic Structures

The amygdala modulates emotional memory and threat perception. Amygdala hyper activation or degeneration has been linked with inappropriate fear responses and reactive aggression in dementia patients.

Hypothalamus and Brainstem

The hypothalamus is involved in autonomic and endocrine responses to stress and aggression. The periaqueductal gray (PAG) and brainstem circuits also modulate reactive aggression through serotonergic pathways.

Neurochemical Imbalances in Aggression

Aggression in dementia is strongly influenced by neurotransmitter dysfunction. The primary systems involved are:

Table 1: Neurotransmitter changes contributing to aggression in dementia

Neurotransmitter	Normal Function	Dysfunction in Dementia	Effect on Behaviour

Dopamine (DA)	Motivation, reward, executive function	Dysregulated in frontal-striatal circuits	Impulsivity, irritability
Serotonin (5-HT)	Mood regulation, aggression control	Decreased in limbic structures, particularly in FTD	Increased aggression, irritability
Acetylcholine (ACh)	Memory, attention	Loss of cholinergic neurons (especially in AD)	Disorientation, frustration, agitation
Glutamate	Excitatory signalling	Excitotoxicity in various brain regions	Neurodegeneration, hyperarousal
GABA	Inhibitory neurotransmission	Deficiency linked to disinhibition	Hyperactivity, agitation

Serotonin Deficiency

Serotonergic dysfunction is perhaps the most well-established biochemical contributor to aggression. Postmortem studies and cerebrospinal fluid (CSF) analyses show reduced serotonin levels in aggressive dementia patients. SSRIs, which enhance serotonergic tone, have shown modest success in reducing aggression in clinical trials.

Dopaminergic Dysregulation

Hyperdopaminergic activity in mesolimbic circuits and reduced dopaminergic control in prefrontal regions may contribute to heightened agitation and paranoia. Antipsychotics, by acting as dopamine D2 receptor antagonists, aim to mitigate these symptoms but often come with adverse effects.

Dementia Subtypes and Aggression Patterns

Different types of dementia display distinct patterns of aggression based on the regions affected and their neuropathological mechanisms:

Table 2: Dementia Subtypes and Their Link to Aggression

Dementia Type	Key Pathology	Aggression Characteristics
Alzheimer's Disease	Amyloid plaques, neurofibrillary tangles	Late-stage irritability, resistiveness to care
Frontotemporal Dementia (FTD)	Frontal and temporal lobe atrophy	Early-onset impulsive, socially inappropriate aggression
Lewy Body Dementia	α-synuclein inclusions	Hallucination-induced aggression, fluctuating cognition
Vascular Dementia	Cerebrovascular lesions	Abrupt mood shifts, frustration due to cognitive decline

Role of Neuro inflammation

Neuro inflammation is increasingly recognized as a central factor in both cognitive decline and behavioural disturbances. Activated microglia release proinflammatory cytokines such as IL-1β, TNF-α, and IL-6, which can exacerbate synaptic dysfunction and neuronal death. These inflammatory mediators have been correlated with heightened aggression in animal models and human studies of dementia.

Environmental and Behavioural Modulators

Apart from structural and biochemical changes, environmental and psychosocial factors play a major role in modulating aggression. These include:

- Pain and discomfort
- Poor communication or misunderstanding
- Overstimulation or under-stimulation
- Change in caregivers or routines
- Sensory impairments (e.g., poor vision/hearing)

Summary and Clinical Implications

Aggression in dementia is the result of multifactorial disturbances involving disrupted neural circuits, neurotransmitter imbalances, neuroinflammation, and environmental triggers. A clear understanding of these mechanisms is essential for developing targeted pharmacological and non-pharmacological strategies. The next chapter will explore how current pharmacological approaches—particularly the use of antipsychotics—fit into this complex pathophysiological landscape.

Chapter 3: Overview and Classification of Antipsychotics

Introduction

Antipsychotics are a cornerstone in managing severe behavioural disturbances in dementia, particularly when non-pharmacological strategies are inadequate. Initially developed for schizophrenia and psychotic disorders, their use has expanded to address symptoms like aggression, agitation, and hallucinations in elderly dementia patients. However, antipsychotics are not without controversy; concerns about safety, tolerability, and regulatory limitations complicate their clinical use. Understanding their classification, mechanisms of action, pharmacological profiles, and suitability in dementia-related aggression is fundamental for optimizing patient outcomes.

Classification of Antipsychotics

Antipsychotics are broadly classified into two major categories:

Table 3: Classification of Anti psychotics

Class	Examples	Primary Receptor Targets	Key Features
Typical (First-Generation)	Haloperidol, Chlorpromazine, Fluphenazine	D2 receptor antagonism	High extrapyramidal side effects (EPS)
Atypical (Second-Generation)	Risperidone, Olanzapine, Quetiapine, Aripiprazole	D2, 5-HT2A antagonism	Lower EPS risk, higher metabolic side effects

Mechanism of Action

Dopamine Hypothesis

The central pharmacological action of antipsychotics involves dopamine D2 receptor antagonism, which reduces dopaminergic hyperactivity, a factor often associated with agitation and psychosis in dementia. Excess dopamine in mesolimbic pathways is implicated in behavioural symptoms, while blockade in the nigrostriatal tract contributes to extrapyramidal symptoms (EPS).

Serotonin-Dopamine Antagonism (Atypicals)

Atypical antipsychotics exhibit dual action on:

- 5-HT2A receptors: Modulate dopamine release in key brain regions
- D2 receptors: Reduce psychotic symptoms without full receptor blockade



Figure 2: Mechanism of action of typical vs atypical antipsychotics

Comparison of Commonly Used Antipsychotics in Dementia

Table 4: Pharmacological Profile of Common Antipsychotics Used in Dementia

Drug	Class	Half-Life (hrs)	Sedation	EPS Risk	Cardiovascular Risk	Special Considerations
Haloperidol	Typical	14–26	Low	High	Moderate	Often used in acute agitation
Risperidone	Atypical	20	Moderate	Moderate	Increased stroke risk	Only antipsychotic approved for short-term use in dementia in some countries
Olanzapine	Atypical	21–54	High	Low	High (metabolic)	Weight gain, hyperlipidaemia
Quetiapine	Atypical	6–7	High	Low	Low	Preferred for Parkinsonian dementia
Aripiprazole	Atypical	75–146	Low	Very low	Low	Partial agonist, fewer side effects

Clinical Pharmacokinetics and Considerations in the Elderly

In geriatric patients, pharmacokinetics is significantly altered due to:

- Decreased renal and hepatic function
- Increased body fat percentage (affecting lipophilic drugs like olanzapine)
- Higher sensitivity to CNS-active agents

These factors necessitate "start low, go slow" dosing, with regular monitoring of side effects.

Efficacy in Dementia-Related Aggression

Atypical antipsychotics have shown modest but statistically significant benefits in controlling aggression and agitation. Risperidone is among the most studied agents and has regulatory approval for short-term use (up to 6–12 weeks) in some countries.

A meta-analysis by Schneider et al. (2006) of 15 randomized trials demonstrated that risperidone and olanzapine significantly reduced behavioural symptoms but increased risk of adverse events and mortality. Haloperidol, though effective, is associated with a higher

incidence of EPS and should be limited to acute settings.

Adverse Effects Profile

Table 5

Adverse Effect	Typical Antipsychotics	Atypical Antipsychotics
Extrapyramidal Symptoms	High	Low to moderate
Tardive Dyskinesia	High	Moderate
Sedation	Low	High (esp. quetiapine, olanzapine)
Orthostatic Hypotension	Moderate	Moderate
Stroke and Mortality Risk	Moderate	Increased (esp. risperidone)
Metabolic Syndrome	Rare	Common (esp. olanzapine)

Regulatory Warnings

- FDA Black Box Warning: Increased mortality in elderly patients with dementia-related psychosis (2005)
- NICE Guidelines: Recommend antipsychotic use only when there is severe distress or risk of harm
- Beers Criteria (American Geriatrics Society): Caution or avoid antipsychotic use in older adults unless absolutely necessary

Recent Trends and Developments

- Long-acting injectable antipsychotics (LAIs) are under evaluation for reducing caregiver burden and improving compliance.
- New agents such as pimavanserin (a selective 5-HT2A inverse agonist) are being tested in dementia-related psychosis with reduced risk profiles.

Summary

Antipsychotics are a valuable but risky pharmacological option in managing aggression in dementia. Their use should be informed by a thorough understanding of their classification, mechanism, and side effect profile. Atypical antipsychotics offer a better safety profile compared to typical ones, but none are free from risks—especially in frail, elderly patients. Judicious use, guided by current clinical guidelines and patient-specific factors, is critical.

Chapter 4: Efficacy of Antipsychotics in Dementia

Introduction

Aggression and agitation are among the most disruptive behavioural and psychological symptoms of dementia (BPSD), affecting up to 90% of patients during the disease course. The pharmacological management of these symptoms has often relied on antipsychotic medications, primarily due to their dopamine-blocking and serotonergic-modulating effects. However, the therapeutic efficacy of antipsychotics in dementia-related aggression remains a topic of ongoing debate. This chapter critically examines clinical evidence from randomized controlled trials, systematic reviews, and meta-analyses to determine the efficacy of both typical and atypical antipsychotics in treating aggression in dementia.

Defining Efficacy in Dementia-Related Aggression

Efficacy in this context is generally measured using standardized behavioural rating scales, such as:

- Neuropsychiatric Inventory (NPI)
- Cohen-Mansfield Agitation Inventory (CMAI)
- Brief Psychiatric Rating Scale (BPRS)
- Clinical Global Impression (CGI) scale

A clinically significant response is often defined as a ≥30% reduction in total aggression/agitation score on these scales.

Evidence from Randomized Controlled Trials (RCTs)

Risperidone

Risperidone has shown the most consistent evidence among atypical antipsychotics in managing aggression. A pivotal double-blind, placebo-controlled study by Katz et al. (1999) demonstrated significant reductions in hostility and aggression in Alzheimer's patients treated with risperidone (1–2 mg/day) compared to placebo.

Another trial by De Deyn et al. (1999) involving 345 patients showed that risperidone was effective in reducing aggressive behaviour, with the most notable results at lower doses (0.5–1.0 mg/day).

Olanzapine

Olanzapine has shown mixed results. In a study by Street et al. (2000), olanzapine (5–10 mg/day) significantly reduced NPI aggression subscale scores compared to placebo. However, it was also associated with increased sedation and weight gain.

Quetiapine

Quetiapine has not consistently demonstrated superiority over placebo in terms of aggression reduction. Tariot et al. (2006) found quetiapine (mean dose 200 mg/day) to be comparable to placebo but better tolerated than risperidone.

Haloperidol

Haloperidol is effective, particularly in acute aggression. A Cochrane review by Lonergan et al. (2002) concluded that haloperidol may be more effective than placebo in short-term use but is limited by severe extrapyramidal side effects.



Figure 3: Summary of Antipsychotic Efficacy Across RCTs

Meta-Analyses and Systematic Reviews

Table 6: Major Meta-Analyses Evaluating Antipsychotic Efficacy in Dementia-Related Aggression

Author/Year	# of Studies	Drugs Evaluated	Key Findings
Schneider et al. (2006)	15 RCTs	Risperidone, Olanzapine, Aripiprazole	Small but statistically significant effect; ↑ mortality risk
Maher et al. (2011)	91 trials	All SGAs	SGAs better than placebo in aggression reduction
Tampi et al. (2016)	23 RCTs	All antipsychotics	Modest efficacy; highest for risperidone and olanzapine

Seitz et al. (2013)	20 studies	Atypical antipsychotics	Efficacy at low doses; adverse events increase with dose

Dose-Response Relationship

Several studies have shown a non-linear dose-response curve, where lower doses of atypical antipsychotics, especially risperidone, provide optimal therapeutic effects with fewer side effects. For example, a 0.5 mg/day dose of risperidone is often effective, while doses above 2 mg/day significantly increase the risk of cerebrovascular events [6].

Duration of Treatment

- Most RCTs indicate maximum benefit within 6–12 weeks of treatment.
- Long-term use (>12 weeks) is associated with diminishing efficacy and increased risk of adverse events.
- Guidelines recommend a tapering strategy after clinical stabilization unless symptoms re-emerge.

Comparative Efficacy: Typical vs. Atypical Antipsychotics

Table 7

Parameter	Typical (e.g., Haloperidol)	Atypical (e.g., Risperidone, Olanzapine)
Efficacy in Aggression	Moderate	High (especially risperidone)
Time to Onset	Rapid (24–72 hrs)	Slower (3–7 days)
EPS Risk	High	Low to moderate
Mortality/CVA Risk	High	Moderate to high (dose-dependent)
Cognitive Side Effects	Higher	Lower (except olanzapine)

Placebo Effect and Non-Pharmacological Confounding

Placebo responses in dementia trials are surprisingly high. In some studies, over 30% of placebo-treated patients showed marked reductions in aggression, possibly due to environmental modifications, caregiver attention, and regular assessments.

This underscores the importance of including behavioural and environmental interventions alongside pharmacotherapy.

Gaps in Efficacy Research

- Underrepresentation of real-world settings (e.g., long-term care facilities)
- Limited head-to-head comparisons of antipsychotics
- Scarce data on minority populations and patients with comorbidities
- Need for longer-term efficacy and safety data

Summary and Clinical Implications

Antipsychotics, particularly risperidone and olanzapine, demonstrate modest efficacy in managing aggression in dementia, especially when used for short durations at low doses. However, these benefits must be weighed against substantial risks, including cerebrovascular events and mortality. Clinicians must consider patient-specific factors, coexisting conditions, and non-pharmacological strategies when initiating therapy.

Chapter 5: Risks and Adverse Effects of Antipsychotics in Dementia

Introduction

While antipsychotics offer therapeutic benefit in reducing aggression and other neuropsychiatric symptoms in dementia, their use is shadowed by a significant risk profile, particularly in elderly populations. Numerous studies and regulatory authorities have raised concerns regarding their association with increased mortality, cerebrovascular adverse events (CVAE), metabolic complications, extrapyramidal symptoms (EPS), cognitive worsening, and infections. These risks are dose-dependent,

drug-specific, and patient-specific, making cautious use imperative in dementia care.

Overview of Common Adverse Effects

Table 8: Overview of Key Adverse Effects of Antipsychotics in Dementia

Adverse Effect	Typical Antipsychotics	Atypical Antipsychotics
Sedation	Moderate	High (esp. olanzapine, quetiapine)
Extrapyramidal symptoms (EPS)	High	Low to moderate
Tardive Dyskinesia	High	Moderate
Metabolic Syndrome	Rare	Common (esp. olanzapine)
Cognitive Decline	Moderate	Moderate to high
Cerebrovascular Events (CVAE)	High	Moderate to high (esp. risperidone)
Increased Mortality	High	Moderate to high
Orthostatic Hypotension	Moderate	Moderate
QTc Prolongation	High	Moderate (esp. ziprasidone)
Falls and Fractures	Moderate	High

Mortality Risk

One of the most alarming findings is the association of antipsychotics with increased all-cause mortality in dementia patients. A 2005 FDA alert based on 17 randomized, placebo-controlled trials noted that atypical antipsychotics are associated with a 1.6- to 1.7-fold increase in mortality compared to placebo [1].

Meta-analyses show mortality rates of approximately:

- 4.5% in antipsychotic-treated patients
- 2.6% in placebo groups over 10–12 weeks

Figure 1: Forest plot showing odds ratio for mortality with antipsychotic use in dementia patients across RCTs.

Cerebrovascular Adverse Events (CVAEs)

Antipsychotic use increases the risk of stroke and transient ischemic attacks, particularly with risperidone and olanzapine.

- Risk Ratio: Up to 2.3-fold increase in CVAEs
- Mechanism: Possibly linked to hypotension, arrhythmias, increased platelet aggregation, and endothelial dysfunction

Risperidone is associated with the highest risk, especially in females and those with a history of CVA or atrial fibrillation [2].

Extrapyramidal Symptoms (EPS)

Typical antipsychotics like haloperidol are notorious for EPS, including:

- Parkinsonism
- Akathisia
- Dystonia
- Tardive dyskinesia

These are less common with atypicals but not absent. Risperidone and aripiprazole may still induce EPS, especially at higher doses or in combination with other dopamine antagonists.

Table 9: Comparison of EPS Risk

Drug	EPS Risk (High to Low)
Haloperidol	Very High
Risperidone	Moderate
Olanzapine	Low
Quetiapine	Very Low

Aripiprazole	Very Low

Sedation and Cognitive Worsening

Sedation is a frequent and dose-limiting side effect, particularly with quetiapine and olanzapine. Sedation may result in:

- Reduced mobility
- Increased risk of pressure ulcers
- Daytime drowsiness
- Social withdrawal

Additionally, studies indicate cognitive decline is accelerated in patients on long-term antipsychotic therapy. Cognitive adverse effects may be due to anticholinergic load and dopaminergic suppression [3].

Metabolic Side Effects

Atypical antipsychotics are linked with:

- Weight gain
- Hyper glycaemia
- Dyslipidaemia

Olanzapine and clozapine are particularly associated with metabolic syndrome, increasing cardiovascular risk in an already vulnerable population.

Figure 2: Chart showing metabolic side effects incidence with atypical antipsychotics (olanzapine > quetiapine > risperidone > aripiprazole)

Falls, Fractures, and Orthostatic Hypotension

Falls are a leading cause of morbidity in older adults with dementia. Antipsychotics contribute through:

- Sedation
- Orthostatic hypotension
- Impaired coordination

Orthostatic hypotension occurs through α1-adrenergic blockade, particularly notable with quetiapine and risperidone.

QT Prolongation and Cardiac Toxicity

Some antipsychotics—especially ziprasidone, haloperidol (IV), and risperidone—prolong the QT interval, potentially leading to torsades de pointes or sudden cardiac death.

Risk is compounded in elderly patients taking other QT-prolonging drugs (e.g., SSRIs, macrolides).

Pneumonia and Infections

Antipsychotic use is linked to a 30–60% increased risk of pneumonia, especially within the first 30 days of initiation [4]. Mechanisms include:

- Sedation and aspiration
- Anticholinergic-induced dry mouth
- Immune modulation

Drug Interactions

Elderly patients with dementia are often on multiple medications. Antipsychotics may interact with:

- SSRIs (CYP2D6 inhibitors) – ↑ Risperidone levels
- Anticholinergics – Cognitive decline, constipation
- Benzodiazepines – Synergistic sedation and falls

Risk Factors for Adverse Events

Table 10: Major Risk Factors Increasing Antipsychotic-Related Adverse Events in Dementia

Risk Factor	Associated Complication
Age > 80	Higher mortality and CVAE risk
History of stroke	Increased risk of recurrent CVA
Atrial fibrillation	CVAE, hypotension
Multiple comorbidities	Increased sedation, QT prolongation
Polypharmacy	Drug interactions
Low BMI	Enhanced drug sensitivity

Strategies to Minimize Risk

1. Risk-Benefit Assessment before prescribing
2. Start low, go slow: Use minimum effective dose
3. Short duration: Reassess within 6–12 weeks
4. Monitor: For EPS, metabolic labs, QT interval
5. Review medications for interactions
6. Deprescribe once symptoms stabilize

Summary

Antipsychotics present a high-risk intervention for dementia-related aggression. Despite their potential benefits in acute settings, especially with risperidone and olanzapine, their long-term use is associated with serious adverse effects including mortality, stroke, and cognitive decline. A judicious, individualized, and guideline-based approach is essential, favouring the lowest dose for the shortest time, and prioritizing safer alternatives when possible.

Chapter 6: Non-Pharmacological Alternatives and Adjuncts for Managing Aggression in Dementia

Introduction

The management of aggression and agitation in dementia is complex, requiring a multidimensional and patient-centred approach. Given the considerable risks associated with antipsychotic use—including increased mortality and cerebrovascular events—there has been a shift toward exploring non-pharmacological interventions as first-line strategies. These interventions not only minimize harm but also often improve patient quality of life, functional ability, and caregiver satisfaction. This chapter examines various non-drug therapies, their evidence base, and how they integrate with or reduce reliance on antipsychotics.

Rationale for Non-Pharmacological Interventions

Non-pharmacological approaches are recommended as first-line treatment for behavioural and psychological symptoms of dementia (BPSD), including aggression, by several international guidelines (NICE, APA, WHO).

Key rationales include:

- High burden of antipsychotic side effects
- Behavioural symptoms often triggered by unmet needs (e.g., pain, boredom, sensory deficits)
- Potential for long-term behavioural improvements
- Focus on holistic, person-centred care

Categories of Non-Pharmacological Interventions

Table 11: Classification of Non-Pharmacological Interventions for Aggression in Dementia

Category	Examples	Primary Focus
Sensory Stimulation	Music therapy, aromatherapy, massage, light therapy	Relaxation and emotional regulation
Behavioural Therapy	Cognitive-behavioural therapy (CBT), positive reinforcement	Habit modification, emotional reframing
Cognitive and Reminiscence	Validation therapy, reminiscence therapy, reality orientation	Enhancing identity and social connection
Environmental Modifications	Noise control, furniture layout, lighting adjustment	Reducing triggers and confusion
Physical and Social Activities	Exercise, dance, gardening, pet therapy	Reducing boredom and restlessness
Caregiver Education and Training	Skills training, communication techniques	Prevention and de-escalation of aggression

Sensory Stimulation Approaches

Music Therapy

Music therapy is one of the most evidence-based non-pharmacological approaches in dementia care. It reduces aggression by:

- Stimulating memory and emotions
- Reducing anxiety and boredom
- Enhancing social interaction

A meta-analysis by van der Steen et al. (2018) showed that individualized music therapy reduced aggression scores significantly when implemented 2–3 times per week for 6–12 weeks [1].

Aromatherapy

Lavender and lemon balm essential oils are used in controlled trials to reduce agitation. Aromatherapy massage shows even greater benefits by combining tactile stimulation.



Figure 4: Illustration of how sensory inputs influence mood regulation in dementia patients (music → limbic system activation; aromatherapy → olfactory-limbic link)

Light Therapy

Bright light exposure has shown modest improvements in sleep-wake cycles and aggression, especially in sundowning syndrome.

Cognitive and Psychosocial Therapies

Reminiscence Therapy

This technique encourages patients to discuss past experiences, often facilitated by photographs, music, or family stories. It strengthens personal identity and reduces aggression caused by confusion or fear.

Validation Therapy

Instead of correcting delusional beliefs, validation therapy encourages empathetic engagement, reducing conflict and frustration.

Reality Orientation

This approach reorients the patient to time, place, and person, but must be used carefully—especially in late-stage dementia, where it may cause distress.

Environmental Modifications

Behavioural symptoms in dementia are often a response to environmental stressors. Simple changes can substantially reduce aggression.

Table 12: Environmental Triggers and Mitigations

Trigger	Mitigation Strategy
Loud noises	Noise-reducing flooring, soft music
Clutter or complex spaces	Clear signage, color-contrast doors

Poor lighting	Consistent circadian lighting systems
Lack of routine	Scheduled meals, activities, rest periods

Physical and Social Activity-Based Therapies

- Exercise programs (e.g., walking, Tai Chi) improve mood and reduce agitation
- Animal-assisted therapy (e.g., petting dogs) provides comfort and engagement
- Art and gardening allow creative expression, reducing boredom and behavioural outbursts

Caregiver Training and Support

Aggression often stems from communication mismatches. Caregiver education improves recognition of triggers and de-escalation skills.

Key strategies taught:

- Use of calm, non-threatening voice
- Avoid confrontation or correcting delusions
- Distraction and redirection techniques
- Managing personal stress levels

Programs like the DICE (Describe, Investigate, Create, Evaluate) approach and the ABC (Antecedent-Behaviour-Consequence) framework have been validated for caregiver-guided behaviour management.

Technology-Assisted Interventions

- Telepresence robots and video-call tools reduce isolation-related aggression
- Motion-sensing alarms and fall detectors improve safety
- Digital reminiscence tools (e.g., touchscreen tablets) help reconnect patients with memories



Figure 5: Diagram showing technology integration in home-based dementia care (wearables, apps, teleconsultation)

Comparative Efficacy with Pharmacological Treatments

Table 13: Efficacy of non-pharmacological vs Pharmacological Approaches

Outcome	Antipsychotics	Non-Pharmacological Interventions
Aggression Reduction	Moderate (short-term)	Moderate to high (long-term, individualized)
Side Effects	High	Minimal
Caregiver Satisfaction	Low	High

Mortality Risk	Increased	None
Time to Onset	Fast (1–2 weeks)	Slower (2–4 weeks)

Challenges in Implementation

- Requires trained staff and consistent resources
- Caregivers may be unaware or sceptical
- Lack of standardized protocols across institutions
- Shortage of funding for art/music therapists

Integration with Pharmacological Management

A blended model combining low-dose antipsychotics and individualized non-pharmacological strategies shows promise:

- Start with behavioural interventions
- Introduce medications if symptoms persist or pose danger
- Taper drugs as soon as possible while sustaining non-drug methods

Summary and Clinical Recommendations

Non-pharmacological interventions are first-line and essential in managing aggression in dementia. Music therapy, caregiver training, environmental changes, and structured activities are supported by a growing body of evidence and are generally safe. Successful implementation requires interdisciplinary collaboration, staff training, and system-level support.

Chapter 7: Ethical and Legal Considerations in the use of Antipsychotics for Dementia

Introduction

The use of antipsychotic medications in the management of dementia-related aggression presents profound ethical and legal dilemmas. These challenges stem from the delicate balance between alleviating suffering and preserving autonomy, preventing harm and avoiding overmedicalization, and the obligation to act in the best interest of a cognitively impaired individual. Inappropriate or prolonged use of antipsychotics in dementia patients can constitute a breach of ethical standards and may violate legal safeguards intended to protect vulnerable populations. This chapter explores the ethical frameworks and legal contexts relevant to antipsychotic use in dementia, emphasizing informed consent, human rights, professional accountability, and policy-level implications.

Ethical Foundations in Geriatric Psychopharmacology

Ethics in dementia care is grounded in the four core principles of biomedical ethics:

1. Autonomy – respecting the individual's right to make informed choices
2. Beneficence – promoting the patient's welfare
3. Non-maleficence – avoiding harm
4. Justice – ensuring fair access and equitable treatment

The clinical decision to initiate an antipsychotic must weigh these principles, recognizing that patients with dementia often have diminished capacity to make autonomous decisions. This creates the need for surrogate decision-makers and raises concerns regarding coercion, consent validity, and informed risk disclosure.

Informed Consent in Dementia Treatment

Obtaining valid informed consent is both an ethical necessity and a legal requirement. However, dementia complicates this process due to cognitive impairment that affects memory, judgment, and understanding.

When a patient lacks decision-making capacity, healthcare providers must:

- Conduct a formal capacity assessment
- Involve a legally authorized representative or next-of-kin
- Provide information in an understandable, compassionate manner
- Document the decision-making process thoroughly

If antipsychotics are initiated, consent must include:

- The reason for use (e.g., risk of harm, distress)
- Expected benefits and alternatives
- Potential adverse effects, including mortality and stroke risk
- Planned duration and monitoring strategy

Failure to secure informed consent or document capacity may expose clinicians and institutions to legal liability and professional censure.

Autonomy vs. Safety: The Ethical Dilemma

Clinicians often face a conflict between respecting a patient's autonomy and ensuring their safety. For example, an agitated patient with dementia may resist treatment or refuse medication. Covert administration, physical restraint, or forced treatment may follow — all of which are ethically controversial.

The least restrictive alternative principle should guide all decisions. Ethical practice requires that:

- The patient's preferences, history, and values be considered
- Non-pharmacological alternatives be tried and documented
- The goals of care be clarified (e.g., comfort vs. behavioural control)

The use of antipsychotics for staff convenience, institutional routine, or behavioural control without documented clinical justification is considered chemical restraint, raising serious ethical and legal concerns.

Chemical Restraint: Definition and Implications

Chemical restraint refers to the use of medication to control behavior not justified by a medical diagnosis or symptom management but rather to manage institutional workflow or staff convenience. This practice is ethically indefensible and often illegal under patient rights laws.

Regulatory agencies in many countries, including India, the UK, Canada, and the USA, have emphasized that antipsychotics should not be used routinely for agitation or aggression and must be time-limited and clearly justified.

Nursing homes and long-term care facilities have been subject to litigation and regulatory penalties for failing to meet consent and documentation standards regarding antipsychotic use.

Human Rights and Dignity in Dementia Care

International conventions, such as the UN Convention on the Rights of Persons with Disabilities (CRPD), stress the importance of respecting the dignity, autonomy, and equality of persons with cognitive impairment. The indiscriminate use of psychotropics can be viewed as a violation of human rights when it:

- Deprives individuals of agency
- Is used to suppress behavior that could be addressed with empathy and engagement
- Is applied uniformly without patient-specific rationale

Preserving dignity in care means treating patients as persons, not problems. This calls for empathetic communication, personalized care, and therapeutic rather than disciplinary intentions.

Legal Frameworks Governing Antipsychotic Use in Dementia

Across jurisdictions, several laws govern medical treatment of individuals with impaired capacity. These include:

- Mental Healthcare Act (2017, India): Mandates informed consent, respect for autonomy, and periodic review of treatment for those with mental illness.
- The Mental Capacity Act (2005, UK): Provides a framework for assessing capacity and supports decisions made in the individual's best interests.
- The Americans with Disabilities Act (ADA) and Patient Self-Determination Act (PSDA) (USA): Emphasize autonomy and equal treatment.

Under these laws:

- Inappropriate use of antipsychotics may qualify as neglect or abuse
- Facilities may face legal action for failure to safeguard residents
- Documentation, oversight, and review of antipsychotic use are legally mandated

Professional Guidelines and Regulatory Oversight

Medical associations and geriatric societies worldwide have issued practice guidelines to ensure ethical prescribing:

- The American Geriatrics Society Beers Criteria (2023) classifies antipsychotics as potentially inappropriate in older adults with dementia unless non-pharmacological interventions have failed.
- The National Institute for Health and Care Excellence (NICE) in the UK advises against routine antipsychotic use and recommends a stepwise approach.
- In India, clinical guidelines from the Indian Psychiatric Society (IPS) urge careful documentation, informed consent, and time-limited trials.

Healthcare providers are ethically obligated to adhere to these standards to protect patient welfare and ensure legal compliance.

The Role of Families and Surrogate Decision-Makers

Family members often serve as surrogate decision-makers, especially when patients lack capacity. Ethical tensions may arise when family wishes conflict with clinical judgment or institutional policies. A family member may demand medications to calm a relative or oppose antipsychotic use entirely.

Clinicians must:

- Communicate risks and benefits transparently
- Respect cultural values and emotions
- Clarify roles and limitations of surrogate decision-makers
- Strive for consensus through shared decision-making

Surrogates must act in accordance with the patient's known or presumed preferences (substituted judgment) or, failing that, in the patient's best interest.

Ethical Use in Emergency Situations

In extreme cases—such as when a patient becomes physically violent—emergency administration of antipsychotics may be ethically permissible without prior consent, under the doctrine of implied consent for life-saving intervention. However, such interventions must be:

- Immediately necessary
- Time-limited
- Subject to post-hoc justification and documentation
- Reported to family and legal authorities as required

Frequent reliance on emergencies to justify antipsychotic use signals poor care planning and warrants review.

Ethical Implications of Research in Dementia Patients

Clinical research on antipsychotics in dementia also raises ethical concerns, such as:

- Enrolling patients with impaired consent capacity
- Withholding treatment from placebo groups
- Inadequate representation of non-Western populations
- Long-term safety monitoring

Ethical research must include:

- Ethics committee approval
- Surrogate consent protocols
- Safety monitoring boards
- Transparent risk-benefit disclosures

Institutional Responsibility and Ethical Climate

Institutions such as hospitals, nursing homes, and care facilities are ethically responsible for fostering a culture of ethical care. This includes:

- Training staff in dementia-sensitive care

- Monitoring and auditing psychotropic prescriptions
- Providing access to behavioural specialists
- Encouraging ethical reflection and interdisciplinary consultation

Administrators must ensure that cost-efficiency or staffing limitations do not compromise ethical patient care.

Summary and Clinical Implications

Antipsychotic use in dementia demands a careful balance between ethical obligation, legal standards, and compassionate care. Clinicians must prioritize patient dignity, informed consent, and non-pharmacological alternatives. Ethical practice requires transparency, vigilance, and patient-centered care tailored to each individual's needs, preferences, and rights. Institutions and policymakers must support systems that promote ethical decision-making and reduce unnecessary reliance on high-risk medications.

Chapter 8: Future Directions and Recommendations in Managing Dementia-Related Aggression

Introduction

Aggression in dementia is a multifaceted neuropsychiatric challenge that poses significant burdens on patients, caregivers, and healthcare systems. Despite the current reliance on antipsychotics, the risks associated with these medications underscore the need for safer, more effective, and individualized interventions. Future directions in dementia care must be interdisciplinary, combining innovations in pharmacology, technology, psychosocial therapy, and policy frameworks. This chapter discusses emerging therapies, research gaps, policy reforms, and practical recommendations for improving the management of aggression in dementia.

Limitations of Current Approaches

Current strategies, particularly the use of conventional antipsychotics, are often:

- Symptom-targeted rather than disease-modifying
- Associated with high morbidity and mortality
- Poorly individualized
- Under-regulated in some long-term care environments

Emerging Pharmacological Alternatives

Novel Antipsychotics with Improved Safety Profiles

Newer agents such as pimavanserin and brexpiprazole offer hope for reduced adverse effect profiles.

- Pimavanserin is a selective 5-HT2A inverse agonist approved for Parkinson's disease psychosis and being explored for Alzheimer's-related psychosis. It lacks dopaminergic activity, reducing EPS and metabolic risks [1].
- Brexpiprazole shows reduced side effects and better tolerability in older populations. It's under evaluation in multiple Phase III trials for dementia-related agitation.

Table 14: Comparison of Emerging vs Traditional Antipsychotics

Drug	Mechanism	EPS Risk	Sedation	FDA Status
Haloperidol	D2 antagonist	High	Moderate	Approved (non-specific)
Risperidone	D2/5HT2 antagonist	Moderate	Moderate	Approved (short-term)
Pimavanserin	5HT2A inverse agonist	Minimal	Low	Investigational in dementia
Brexpiprazole	Partial D2/5HT1A agonist	Low	Low	Phase III trials ongoing

Anti-inflammatory and Neuroprotective Agents

Emerging evidence suggests that neuroinflammation may contribute to

aggression and agitation in dementia. Anti-inflammatory agents such as:

- Minocycline
- TNF-α inhibitors
- COX-2 inhibitors (celecoxib)



Figure 5: Schematic of neuro inflammation-induced behavioural dysregulation in dementia and potential anti-inflammatory targets.

Cannabinoids and Serotonergic Modulators

- Dronabinol and other cannabinoids have shown mild to moderate benefits in small-scale studies.
- Serotonergic modulators such as SSRIs (e.g., citalopram) are being repurposed for aggression control, with better tolerability.

Personalized and Precision Medicine Approaches

Future treatment models will likely shift from "one-size-fits-all" pharmacotherapy to biomarker-guided, individualized care based on:

- Genetic profiles (e.g., APOE4, COMT polymorphisms)
- Neuroimaging markers of aggression
- Inflammatory biomarkers

Artificial intelligence (AI) and machine learning can aid in predictive modelling and stratifying risk of aggression and drug response.

Advancements in Non-Pharmacological Interventions

Non-pharmacological approaches are gaining technological and scientific refinement:

- Virtual reality (VR) therapy to provide immersive, calming environments
- AI-driven music therapy tailored to mood and behaviour patterns
- Robotic pets for behavioural engagement and calming
- Telemedicine for early identification and remote intervention

Integrated and Multidisciplinary Care Models

Future dementia care must be grounded in:

- Geriatric psychiatry
- Neurology
- Social work
- Nursing and caregiver training

Models such as Collaborative Care for Older Adults with Dementia (CCOAD) and DICE (Describe-Investigate-Create-Evaluate) are being expanded and evaluated for broader implementation.

These models promote:

- Shared decision-making
- Comprehensive behavioural assessment
- Ethical prescribing and deprescribing practices

Health Policy and System-Level Reforms

To promote safer dementia care, governments and institutions should implement:

- Strict antipsychotic use regulations
- Mandatory non-pharmacological trials before prescribing
- Centralized monitoring registries for psychotropic use in dementia
- Reimbursement incentives for non-drug therapies
- Standardized caregiver education modules

The CMS (Centres for Medicare & Medicaid Services) in the USA has successfully reduced inappropriate antipsychotic use by over 30% through the National Partnership to Improve Dementia Care

Global Perspectives and Disparities

The future must also address inequities in dementia care:

- Low- and middle-income countries (LMICs) often lack access to behavioural therapies and face medication overuse
- Cultural beliefs may influence how aggression is interpreted and treated
- International organizations such as WHO must develop context-sensitive protocols and capacity-building strategies

Global collaboration through data sharing, open-access training, and standardized care templates will be essential for equity in dementia aggression management.

Research Gaps and Opportunities

Despite progress, critical research gaps remain:

- Long-term safety and efficacy of new drugs
- Mechanisms linking neurodegeneration and aggression
- Ethical frameworks for AI-driven behavioural prediction
- Cost-effectiveness of combined therapy models

Future clinical trials should:

- Use diverse populations
- Incorporate caregiver burden metrics
- Include real-world implementation strategies

Practical Recommendations for Clinicians

1. Prioritize non-pharmacological strategies in all care plans.
2. If antipsychotics are required, use the lowest effective dose and regularly reassess.
3. Monitor for adverse effects and consider early deprescribing.
4. Advocate for caregiver support, including training and respite care.
5. Document behaviour patterns clearly before initiating medications.
6. Encourage use of technology-assisted interventions where available.
7. Collaborate in multidisciplinary teams for holistic patient assessment.

Conclusion

Managing aggression in dementia requires a paradigm shift—from reactive, risk-prone pharmacotherapy to proactive, preventive, and personalized care. The future lies in integrating safer pharmacological agents, advanced non-drug interventions, ethical practice, and system-level reforms. Collaboration between clinicians, researchers, caregivers, and policymakers will be the cornerstone of progress. As the global burden of dementia grows, so too must our commitment to compassionate, evidence-based, and patient-centered approaches to behavioural management.

Annexure

Term	Definition
Aggression in Dementia	Verbal or physical hostility or resistance observed in people with dementia.
Antipsychotics	A class of drugs used to manage psychosis, agitation, and aggression.

Atypical Antipsychotics	Newer generation antipsychotics with fewer extrapyramidal side effects.
BPSD	Behavioural and Psychological Symptoms of Dementia, includes aggression, etc.
D2 Receptor	Dopamine receptor type 2; target of many antipsychotics.
Chemical Restraint	Use of drugs to restrict a person's freedom without medical justification.
Neuroinflammation	Inflammatory response in the brain, often associated with neurodegeneration.
Informed Consent	Voluntary agreement to treatment after being informed of its risks/benefits.
Non-Pharmacological Care	Behavioural and environmental strategies to manage symptoms without medication.
Deprescribing	Systematic process of tapering or stopping medications that may be harmful.

Reference

1. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs. 2010;24(9):729–739. doi: 10.2165/11319240-000000000-00000
2. World Health Organization. **Dementia** [Internet]. Geneva: WHO; 2023 [cited 2025 Jun 30]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
3. Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011 Sep;7(5):532–9.
4. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015 Mar 2;350:h369.
5. Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016 Jan;7(5):229–45.
6. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294(15):1934–43.
7. National Institute for Health and Care Excellence. **Dementia: assessment, management and support for people living with dementia and their carers. NICE Guideline NG97** [Internet]. London: NICE; 2018 [cited 2025 Jun 30]. Available from: https://www.nice.org.uk/guidance/ng97
8. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308–14. doi:10.1212/wnl.44.12.2308
9. Tekin S, Cummings JL. Frontal–subcortical neuronal circuits and clinical neuropsychiatry: An update. J Psychosom Res. 2002 Jul;53(2):647–54. doi:10.1016/S0022-3999(02)00428-2
10. Hsu WY, Lane HY, Lin CH. Effect of antipsychotics on dementia-related behavioral and psychological symptoms: Meta-analysis of randomized, placebo-controlled trials. J Clin Psychopharmacol. 2017 Aug;37(4):447–54. doi:10.1097/JCP.0000000000000730
11. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009 May;5(5):245–55. doi:10.1038/nrneurol.2009.39

12. Lanctôt KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: Evidence for dysfunction and potential as a therapeutic target. Drugs Aging. 2004;21(2):147–57. doi:10.2165/00002512-200421020-00005
13. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003 Sep;306(3):821–7. doi:10.1124/jpet.103.052274
14. Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Barak N, et al. Evidence for GABAergic impairment in schizophrenia and its relevance to aggressive behaviour. World J Biol Psychiatry. 2005 Jan;6(3):154–63. doi:10.1080/15622970500239129
15. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010 Feb;6(2):67–77. doi:10.1038/nrneurol.2009.215
16. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006 Jul;368(9533):387–403. doi:10.1016/S0140-6736(06)69113-7
17. Sultzer DL, Melrose RJ, Mahler ME, Mandelkern MA. The neural correlates of aggression in Alzheimer's disease: An FDG-PET study. Int J Geriatr Psychiatry. 2011 Mar;26(3):290–6. doi:10.1002/gps.2526
18. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 2002;47(1):27–38. doi:10.1177/070674370204700107
19. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43. doi:10.1001/jama.294.15.1934
20. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia. JAMA Psychiatry. 2015;72(5):438–45. doi:10.1001/jamapsychiatry.2014.3018
21. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD). Lancet Neurol. 2009 Feb;8(2):151–7. doi:10.1016/S1474-4422(08)70295-3
22. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider LS, et al. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–70. doi:10.1038/sj.npp.1301503
23. Banerjee S. The use of antipsychotic medication for people with dementia: Time for action. Department of Health, UK. 2009. doi:10.13140/2.1.3534.2727
24. Finkel SI, Burns A, Cohen G. Behavioral and psychological symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497–500. doi:10.1017/S1041610297003943
25. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. doi:10.1136/bmj.h369
26. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry. 1999;60(2):107–15. doi:10.4088/JCP.v60n0205
27. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology. 1999;53(5):946–55. doi:10.1212/wnl.53.5.946
28. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with

Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57(10):968–76. doi:10.1001/archpsyc.57.10.968
29. Tariot PN, Schneider LS, Katz IR, Mintzer JE, Street JS, Copenhaver M, et al. Quetiapine treatment of agitation associated with dementia: A randomized, placebo-controlled study. Am J Geriatr Psychiatry. 2006;14(9):767–76. doi:10.1097/01.JGP.0000224356.73376.34
30. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):CD002852. doi:10.1002/14651858.CD002852
31. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91–103. doi:10.2165/00023210-200519020-00001
32. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA. 2011;306(12):1359–69. doi:10.1001/jama.2011.1360
33. Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: A systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45. doi:10.1177/2040622316658463
34. Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, et al. Pharmacological treatments for agitation and aggression in Alzheimer's disease: A systematic review and meta-analysis. CMAJ. 2013;185(10):E439–E445. doi:10.1503/cmaj.121430
35. Ballard C, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–55. doi:10.1038/nrneurol.2009.39
36. Schneider LS, Dagerman KS, Insel PS. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43. doi:10.1001/jama.294.15.1934
37. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological management of behavioral symptoms of dementia. Can J Psychiatry. 2007;52(10):630–46. doi:10.1177/070674370705201003
38. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD003476. doi:10.1002/14651858.CD003476.pub2
39. Knol W, van Marum R, Jansen P, Souverein P, Schobben A, Egberts A. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661–6. doi:10.1111/j.1532-5415.2008.01607.x
40. Wooltorton E. Atypical antipsychotic drugs and stroke. CMAJ. 2004;170(9):1395. doi:10.1503/cmaj.1040410
41. Gill SS, Bronskill SE, Normand S-LT, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86. doi:10.7326/0003-4819-146-11-200706050-00007
42. van der Steen JT, Smaling HJA, van der Wouden JC, Bruinsma MS, Scholten RJ, Vink AC. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018;7(7):CD003477. doi:10.1002/14651858.CD003477.pub4
43. Low LF, Brodaty H, Goodenough B, Spitzer P, Bell JP, Fleming R, et al. The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE): Cluster randomised trial of humour therapy in nursing homes. BMJ Open. 2014;4(1):e003441. doi:10.1136/bmjopen-2013-003441
44. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms

of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9. doi:10.1111/jgs.12730
45. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: Systematic review of randomized controlled trials. Br J Psychiatry. 2014;205(6):436–42. doi:10.1192/bjp.bp.113.141119
46. Abraha I, Rimland JM, Trotta FM, Dell'Aquila G, Cruz-Jentoft A, Petrovic M, et al. Systematic review of non-pharmacological interventions to treat behavioural and psychological symptoms of dementia. J Am Med Dir Assoc. 2017;18(6):493–504. doi:10.1016/j.jamda.2017.02.013
47. Gitlin LN, Marx K, Stanley IH, Hodgson N. Translating evidence-based dementia caregiving interventions into practice: State-of-the-science and next steps. Gerontologist. 2015;55(2):210–26. doi:10.1093/geront/gnu123
48. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43. doi:10.1001/jama.294.15.1934
49. Appelbaum PS. Assessment of patients' competence to consent to treatment. N Engl J Med. 2007;357(18):1834–40. doi:10.1056/NEJMcp074045
50. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9. doi:10.1111/jgs.12730
51. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–42. doi:10.1192/bjp.bp.113.141119
52. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97]; 2018. Available from: https://www.nice.org.uk/guidance/ng97
53. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–79. doi:10.1111/jgs.18372
54. Mental Healthcare Act, 2017. Ministry of Law and Justice, Government of India. Gazette of India; 2017. Available from: https://egazette.nic.in/
55. Ballard C, Banister C, Khan Z, Cummings J, Demos G. Evaluation of the safety, tolerability, and efficacy of pimavanserin for the treatment of dementia-related psychosis. Lancet Neurol. 2019;18(12):1060–69. doi:10.1016/S1474-4422(19)30325-1
56. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91. doi:10.1001/jama.2014.93
57. CMS.gov. National Partnership to Improve Dementia Care in Nursing Homes: Antipsychotic Medication Use Data. Centers for Medicare & Medicaid Services; 2022. Available from: https://www.cms.gov/
58. Mintzer JE, Tune LE. Clinical implications of age-related changes in central cholinergic function. Clin Geriatr Med. 2001;17(2):295–311. doi:10.1016/S0749-0690(05)70048-2
59. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioural and psychological symptoms of dementia. BMJ. 2015;350:h369. doi:10.1136/bmj.h369
60. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46. doi:10.1016/S0140-6736(20)30367-6